Patient characteristics
| Meta-analysis (% (95% CI)) | I2 (%) | Raw numbers | |
|---|---|---|---|
| No of patients | – | – | 509 |
| No of aneurysms treated | – | – | 515 |
| Patient presentations | |||
| Cranial nerve deficit mass effect | 77.0 (65.0 to 86.0) | 81 | 310/511 |
| SAH | 6.0 (4.0 to 9.0) | 0 | 23/511 |
| CCF | 7.0 (5.0 to 9.0) | 0 | 22/511 |
| Treatment modality | |||
| Carotid occlusion | 35.0 (18.0 to 58.0) | 84 | 176/515 |
| Endovascular coiling | 65.0 (42.0 to 82.0) | 84 | 339/515 |
| Cumulative outcomes | |||
| Complete/near complete occlusion at 3 months | 79.0 (69.0 to 87.0) | 71 | 372/477 |
| Improvement in mass effect | 82.0 (67.0 to 91.0) | 71 | 218/266 |
| Retreatment rate | 14.0 (9.0 to 21.0) | 38 | 52/507 |
| Total periprocedural morbidity | 4.0 (3.0 to 7.0) | 0 | 12/514 |
| Periprocedural stroke | 4.0 (3.0 to 6.0) | 0 | 11/515 |
| Periprocedural hemorrhage | 3.0 (2.0 to 6.0) | 0 | 2/515 |
| Periprocedural mortality | 3.0 (2.0 to 6.0) | 0 | 2/515 |
CCF, carotid cavernous fistula; R, retrospective. SAH, subarachnoid hemorrhage.